

NEONATAL AND PEDIATRIC FOCUSED DRUG INFORMATION

NeoFax and Pediatrics: population-specific decision support

Trusted guidance when treating your youngest patients

Clinical decision support tailored to age and indication

Managing drug therapy for a premature two-day-old baby in the neonatal intensive care unit is not the same as treating a six yearold child in the pediatric unit. When it comes to providing safe and effective drug therapy, there are clinically significant differences between neonatal and pediatric populations.


Having access to distinct, population-specific drug information is critical to ensuring the safety of your most vulnerable patients.

Micromedex NeoFax[®] and Pediatrics solutions highlight variations in dosage, administration, pharmacokinetics, monitoring, and potential side effects, which can be different and clinically important across these populations. It offers a clear reference point for treatment options covering medication management, clinical studies, and guideline summaries.

Highlights

- Ensure focus and save time with separate neonatal and pediatric monographs that get you to the relevant population-specific information faster
- Support patient safety with population-specific dosing based on indication and patient age
- Inform off-label treatment decisions with information that provides context, relevance, and caveats around available supporting evidence
- Tailor enteral nutrition support to meet the needs of each patient with easy comparison of multiple products including infant formulas and human milk fortifiers
- Access information when and where you need it with full drug monograph and infant formula content online and on your mobile app





Little lives, big responsibility: Peace of mind when it matters most

Building on the history and reputation of NeoFax, Micromedex neonatal and pediatrics content provides trusted, evidence-based drug information for neonatal and pediatric patients. Its comprehensive editorial processes ensure accuracy, guided by published literature, clinical guidelines, and regulatory information.

The NeoFax and Pediatrics solutions are part of the drug information family of content of Micromedex, your trusted partner for clinical decision support:

Ø

品

Trusted for 50 years by government agencies and clinicians alike

Helps care teams across more than 80 countries support the highest levels of patient care



Accredited by the National Institute for Health and Care Excellence (NICE) for the process used to develop Micromedex content



Available online, and on mobile devices

"As far as my go-to source for pediatrics and neonatal, Micromedex is my number one. That's what I rely on and that is what the neonatologists rely on. When there's something special that the neonatologists want, compounding for a baby, Micromedex is right on top as far as getting you what to use, how much to use, what solution to use, and what the concentration is going to be. We put it on formulary using the compounding solutions that are recommended by Micromedex."

Anthony Bono Pharmacist Englewood Hospital, New Jersey, United States

About Micromedex

Micromedex by Merative is trusted by healthcare professionals across 70 countries to provide award-winning clinical decision support solutions for drug and disease information and patient education. Micromedex was named Best in KLAS 2023 (clinical decision support: point of care clinical reference), is recognized as a CMS compendium, and is accredited by NICE for its robust editorial process.

Learn more at <u>merative.com/clinical-decision-</u> support

About Merative

Merative is a data, analytics and technology partner for the health industry, including providers, payers, life sciences companies and governments. With trusted technology and human expertise, Merative works with clients to drive real progress. Merative helps clients reassemble information and insights around the people they serve to improve healthcare delivery, decision making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022.

Learn more at merative.com

© Merative US L.P. 2024. All Rights Reserved.

Produced in the United States of America September 2024

Merative and the Merative logo are trademarks of Merative US L.P. Other product and service names might be trademarks of Merative or other companies.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on Merative's product plans and strategy as of the date of this publication, which are subject to change by Merative without notice. Nothing contained in this publication is intended to. nor shall have the effect of, creating any warranties or representations from Merative, or stating or implying that any activities undertaken by you will result in any specific performance results. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

MDX-7370528287 Rev 1.0

